Angiotensin II (AT-II)-Receptor Antagonists are Reviewed. Research focused on blocking the renin- angiotensin system (RAS) led to the discovery of angiotensin-converting-enzyme (ACE) inhibitors ...

inhibitor or angiotensin receptor blocker (ARB) drugs. This condition is highly prevalent and is the common reason for an ...

When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a ...

A recent study from Geisinger Medical Center has found that two types of drugs used to treat high blood pressure for the ...

Among women with suspected ischemia with nonobstructive coronary disease, an intensive medical therapy strategy did not ...

The global IgA nephropathy disease treatment market is poised for substantial growth, with projections indicating a robust CAGR of 20.8% during the forecast period from 2022 to 2028. This growth is ...

and associations with morbidity/mortality of renin-angiotensin inhibitors (RASi), angiotensin receptor-neprilysin inhibitors ...

BofA raised the firm’s price target on Travere Therapeutics (TVTX) to $31 from $29 and keeps a Buy rating on the shares. Investors have ...

STOCKHOLM, SE / ACCESS Newswire / March 26, 2025 /Vicore Pharma Holding (STO:VICO) Stockholm, March 26, 2025 - Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, ...